

Thursday January 20, 2022

14:00 – 14:10

Welcome and introduction to the program
(P. Evenepoel, Leuven, Belgium)

14:10 – 16:15

Research Forum Part 1
Chairs: P. D'Haese (Antwerp, Belgium)
& J. Bacchetta (Lyon, France)

14:10 – 14:30 (ML)

Klotho in skeletal pathobiology
(H. Komaba, Tokai, Japan)

14:30 – 14:50 (ML)

Klotho in vascular pathobiology
(R. Mencke, Groningen, Netherlands)

14:50 – 15:10 (FC)

**sKlotho as a biomarker of vascular
and bone damage in moderate
chronic renal failure**
(J. Martín-Virgalas, Oviedo, Spain)

15:10 – 15:30 (FC)

**MicroRNA-145 and microRNA-486
regulate vascular smooth muscle cells
osteogenic differentiation**
(S. Fernández-Villabril, Oviedo, Spain)

15:30 – 15:50 (ML)

**Vascular calcification impairs bone
metabolism**
(M. Mace, Copenhagen, Denmark)

15:50 – 16:10

**Effects of androgen replacement therapy
on bone and vascular complications
in an adenine-induced CKD rat model**
(K. David, Leuven, Belgium)

16:15 – 16:45

Catch up and break

16:45 – 18:00

**CME: Controversies in renal
osteodystrophy: focus on adynamic
bone (disease)**
Part 1 Pathophysiological aspects
Chairs: S. Mazzaferro (Rome, Italy)
& J. Cannata-Andia (Oviedo, Spain)

16:45 – 17:15

**Parathyroid hormone biology
and signaling**
(D. Hansen, Herlev, Denmark)

17:15 – 17:45

**Adynamic bone disease,
a conceptual and diagnostic challenge**
(M. Haarhaus, Stockholm, Sweden)

17:45 – 18:00

Closing remarks
(P. Evenepoel, Leuven, Belgium)

ML: Mini Lecture
FC: Free Communication
P: Pitch

Friday January 21, 2022

14:00 – 14:10

Welcome and introduction to the program
(P. Evenepoel, Leuven, Belgium)

14:15 – 16:00

**CME: Controversies in renal osteodystrophy:
focus on adynamic bone (disease)**
Part 2: Therapeutic challenges
Chairs: M.H. Lafage-Proust (Lyon, France)
& M. Haarhaus (Stockholm, Sweden)

14:10 – 14:25

Antiresorptive agents in advanced CKD: pro
(B. Abrahamsen, Odense, Denmark/Oxford, UK)

14:25 – 14:40

Antiresorptive agents in advanced CKD: con
(M. Cohen-Solal, Paris, France)

14:40 – 15:00

Panel discussion and Q&A

15:00 – 15:15

PTH analogs in early stage CKD
(M. Pazianas, Oxford, UK)

15:15 – 15:30

PTH analogs in advanced stage CKD
(S. Mazzaferro, Rome, Italy)

15:30 – 15:45

Romozumab: potentials and pit-falls in CKD
(R. de Jongh, Amsterdam, The Netherlands)

15:45 – 16:00

Panel discussion and Q&A

16:00 – 16:30

Catch up and break

16:30 – 18:30

Research Forum Part 2
Chairs: A. Ferreira (Lisbon, Portugal)
& G. Spasovski (Skopje, Republic of Macedonia)

16:30 – 16:50 (ML)

**Added value of bone histomorphometry
post-transplant for the assessment of long-term
skeletal health**
(N. Bravenboer, Amsterdam, Netherlands)

16:50 – 17:10 (FC)

**Study of bone strength measured in vivo by impact
microindentation in the peri-renal transplantation
period**
(M.J. Lloret Cora, Barcelona, Spain)

17:10 – 17:30 (FC)

**A 3D in vitro model of impaired osteocytes
activity under exposure to indoxyl sulfate**
(S. Mihaila, Utrecht, Netherlands)

17:30 – 17:50 (FC)

**Bone secondary mineralization, osteocyte expression
of SIBLINGs and sclerostin are conditioned by the
different types of renal osteodystrophy**
(Marie-Hélène Lafage-Proust, Lyon, France)

17:50 – 18:10 (ML)

Mg in bone and vascular health: time to act?
(I Bressendorf, Hillerod, Denmark)

18:10 – 18:20 (P)

Mg in dialysate: a call for a pragmatic study
(G. Meeus, Kortrijk, Belgium)

18:20 – 18:30

Best Abstract Award and Closing Remarks
(P. Evenepoel, Leuven, Belgium)